AHA: Coordination of Emergency Care Ups STEMI Survival Rates

Share this content:
AHA: Coordination of Emergency Care Ups STEMI Survival Rates
AHA: Coordination of Emergency Care Ups STEMI Survival Rates

WEDNESDAY, Nov. 19, 2014 (HealthDay News) -- Improved coordination between paramedics and hospitals can reduce ST-segment elevation myocardial infarction (STEMI) deaths nearly five-fold by getting patients quicker treatment, according to research of an initiative to be presented Wednesday at the annual meeting of the American Heart Association, held from Nov. 15 to 19 in Chicago.

The initiative, called Mission: Lifeline and coordinated through Duke University, was conducted with 484 hospitals and 1,258 emergency medical service agencies in 16 cities. Researchers found it resulted in slight reductions in the time it took to get patients from their first contact with a medical professional into an operating room. But those small reductions had enormous benefits: death rates were dramatically reduced by getting people into surgery even 15 minutes sooner than normal.

As part of the program, researchers helped local agencies craft their own plans for coordinating heart attack care among paramedics, hospital staff, and cardiologists, study coauthor James Jollis, M.D., chairman of Mission: Lifeline, told HealthDay. The goal was to reduce to less than 90 minutes the amount of time between when a paramedic or emergency department worker sees a STEMI patient and when the patient receives reperfusion therapy.

Only 2.3 percent of patients who waited less than 30 minutes in an emergency department for treatment died, compared to 7.7 percent of people who waited for 30 to 45 minutes and 11.2 percent of those who had to wait more than 45 minutes, the researchers found. The results also showed that people who call paramedics during a STEMI receive quicker medical attention. Patients who dialed 911 had their first medical contact 47 minutes after the onset of symptoms, while those who drove themselves to the hospital took 114 minutes to see a health care professional.

Full Article
Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths